文献速递消化道肿瘤与早癌消化内镜

多靶点粪便DNA检测在平均风险结直肠癌筛查人群中的表现

Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

在结肠镜控制的平均风险筛查人群中,多靶点粪便DNA检测对晚期癌前病变的敏感性为46%(55/119),高于FIT的27%(32/119),P<0.001;两者对非进展期或阴性者的特异性分别为89%和93%。MT-sDNA或FIT对高风险进展型进展期腺瘤与低风险进展期腺瘤的检出敏感性无显著差异。

要点

  • MT-sDNA对晚期癌前病变的敏感性高于FIT单用。
  • MT-sDNA特异性低于FIT,需权衡假阳性。
  • 对高风险进展型腺瘤,MT-sDNA与FIT敏感性无显著差异。

核心结论

  • 在平均风险筛查人群中,MT-sDNA检测对晚期癌前病变的敏感性高于FIT单用。
  • MT-sDNA或FIT对高风险进展型进展期腺瘤与低风险进展期腺瘤的检出敏感性无显著差异。

研究设计与样本

  • 前瞻性收集全粪便样本n=1,047,在结肠镜控制的平均风险结直肠癌筛查人群中评估MT-sDNA。
  • MT-sDNA检测KRAS突变、NDRG4和BMP3启动子甲基化及血红蛋白。
  • 与FIT单用(阈值50、75、100血红蛋白/mL)比较检测CRC、晚期癌前病变和非进展期腺瘤的表现。
  • 高风险进展型进展期腺瘤由低覆盖全基因组测序检测特定DNA拷贝数事件定义。

主要发现

  • MT-sDNA检测晚期癌前病变的敏感性为46%(55/119),FIT为27%(32/119),P<0.001。
  • 在非进展期或阴性发现者中,MT-sDNA特异性为89%(791/888),FIT为93%(828/888)。
  • MT-sDNA阳性与多发病变(P=0.005)、较大病变(P=0.03)及管状绒毛状结构病变(P=0.04)相关。
  • MT-sDNA或FIT检出高风险进展期腺瘤(n=19)与低风险进展期腺瘤(n=52)的敏感性无显著差异。

临床怎么用

  • 在平均风险人群筛查中,可考虑MT-sDNA用于提高晚期癌前病变检出。
  • 需注意MT-sDNA特异性低于FIT,阳性结果应结合结肠镜进一步评估。
  • 对高风险进展型腺瘤的检出优势未显现,筛查策略需综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We set out to evaluate the performance of a multitarget stool DNA (MT-sDNA) in an average-risk colonoscopy-controlled colorectal cancer (CRC) screening population. MT-sDNA stool test results were evaluated against fecal immunochemical test (FIT) results for the detection of different lesions, including molecularly defined high-risk adenomas and several other tumor characteristics. METHODS: Whole stool samples (n = 1,047) were prospectively collected and subjected to an MT-sDNA test, which tests for KRAS mutations, NDRG4 and BMP3 promoter methylation, and hemoglobin. Results for detecting CRC (n = 7), advanced precancerous lesions (advanced adenoma [AA] and advanced serrated polyps; n = 119), and non-AAs (n = 191) were compared with those of FIT alone (thresholds of 50, 75, and 100 hemoglobin/mL). AAs with high risk of progression were defined by the presence of specific DNA copy number events as measured by low-pass whole genome sequencing. RESULTS: The MT-sDNA test was more sensitive than FIT alone in detecting advanced precancerous lesions (46% (55/119) vs 27% (32/119), respectively, P < 0.001). Specificities among individuals with nonadvanced or negative findings (controls) were 89% (791/888) and 93% (828/888) for MT-sDNA and FIT testing, respectively. A positive MT-sDNA test was associated with multiple lesions (P = 0.005), larger lesions (P = 0.03), and lesions with tubulovillous architecture (P = 0.04). The sensitivity of the MT-sDNA test or FIT in detecting individuals with high-risk AAs (n = 19) from individuals with low-risk AAs (n = 52) was not significantly different. DISCUSSION: In an average-risk screening population, the MT-sDNA test has an increased sensitivity for detecting advanced precancerous lesions compared with FIT alone. AAs with a high risk of progression were not detected with significantly higher sensitivity by MT-sDNA or FIT.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Bosch LJW, Melotte V, Mongera S, et al. Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population. Am J Gastroenterol. 2019. PMID: 31764091. doi:10.14309/ajg.0000000000000445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。